诉讼核心信息 - 罗森律师事务所提醒在2024年3月7日至2025年5月23日期间购买Savara公司证券的投资者注意2025年11月7日的首席原告截止日期 [1] - 一项针对Savara公司的集体诉讼已被提起 投资者可能有权通过风险代理收费安排获得补偿而无需支付任何自付费用 [1][2] 诉讼指控细节 - 指控称被告作出了虚假和/或误导性陈述和/或未能披露关键信息 [4] - 具体指控包括MOLBREEVI的生物制品许可申请缺乏关于化学、制造和控制的足够信息 导致美国FDA不太可能批准其当前形式的申请 [4] - 指控还指出上述问题使得Savara公司不太可能在其向投资者承诺的时间框架内完成MOLBREEVI BLA的提交 并且监管批准的延迟增加了公司需要筹集额外资本的可能性 [4] 律师事务所背景 - 罗森律师事务所专注于证券集体诉讼和股东衍生诉讼 在全球代表投资者 [3] - 该事务所曾达成针对中国公司的史上最大证券集体诉讼和解 并在2017年被ISS证券集体诉讼服务评为和解数量第一 自2013年以来每年排名前四 [3] - 该事务所已为投资者追回数亿美元 仅在2019年就为投资者确保了超过4.38亿美元的资金 [3]

, /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission-form?prid=171456&wire=4Â ...

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...

, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Savara Inc. (NASDAQ: SVRA). Shareholders who purchased shares of SVRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. The Gross Law Firm 15 West 38th Street, 12th floor New York, NY, 10018 Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm ALLEGATIONS: The complain ...

This is my fourth Savara Inc. (NASDAQ: SVRA ) article, following 07/2025's "Savara: Repairing The Molbreevi aPAP Opportunity After RTF." Savara is a 1-trick pony with its Molbreevi in the treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP) beingWriting under the pseudonym "out of ignorance", I very much regard investing as a learning process. Investing failures are tuition paid. Investing successes enter the trove of lessons learned. In my Seeking Alpha articles I share my experience from decades ...

案件核心信息 - 罗森律师事务所提醒在2024年3月7日至2025年5月23日期间购买Savara Inc (NASDAQ: SVRA) 证券的投资者注意2025年11月7日的首席原告截止日期 [1] - 一项针对Savara的集体诉讼已被提起，指控公司在上述集体诉讼期间做出了虚假和/或误导性陈述 [4] 诉讼指控细节 - 指控称，公司未能披露其治疗罕见肺病的临床试验MOLBREEVI的生物制剂许可申请缺乏足够的化学、制造和控制信息 [4] - 因此，美国FDA不太可能以当前形式批准该BLA，这使得公司不太可能在其向投资者承诺的时间框架内完成BLA的提交 [4] - 监管批准的延迟增加了公司需要筹集额外资金的可能性，导致被告的公开陈述在所有相关时间均存在重大虚假和误导 [4] 律师事务所背景 - 罗森律师事务所专注于证券集体诉讼和股东衍生诉讼，其代表全球投资者 [3] - 该所曾达成针对中国公司的史上最大证券集体诉讼和解，并因2017年和解案件数量被ISS证券集体诉讼服务评为第一 [3] - 自2013年以来，该所每年排名前四，为投资者追回数亿美元，仅在2019年就为投资者确保了超过4.38亿美元 [3]

公司事件概述 - 律师事务所Faruqi & Faruqi正在调查针对Savara Inc的潜在索赔 并提醒投资者关于联邦证券集体诉讼的首席原告申请截止日期为2025年11月7日 [4] - 诉讼指控公司及其高管在2024年3月7日至2025年5月23日期间 通过做出虚假和/或误导性陈述及/或未能披露信息 违反了联邦证券法 [1][6] 诉讼指控的具体内容 - 指控称 Savara提交的MOLBREEVI生物制品许可申请缺乏关于化学、制造和/或控制的足够信息 [6] - 指控称 因此美国食品药品监督管理局不太可能以当前形式批准该申请 且公司不太可能在其向投资者承诺的时间框架内完成提交 [6] - 指控称 MOLBREEVI监管批准的延迟增加了公司需要筹集额外资金的可能性 [6] 事件直接影响 - 2025年5月27日 Savara宣布其MOLBREEVI的BLA收到FDA的拒收函 [7] - 此消息导致公司股价当日下跌090美元/股 跌幅达3169% 收盘报194美元/股 [7]

New York, New York--(Newsfile Corp. - October 6, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the "Class Period"), of the important November 7, 2025 lead plaintiff deadline.SO WHAT: If you purchased Savara securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. W ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- If you have suffered a loss on your Savara Inc. (“Savara” or the “Company”) (NASDAQ:SVRA) investment, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost. Investors have until November 7, 2025 to ask the Court to appoint them as lead plaintiff. [CONTACT THE FIRM IF YOU SUFFERED A LOSS] What Happened? On May ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Savara Inc. ("Savara Inc." or the "Company") (NASDAQ: SVRA) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Savara Inc. investors who were adversely affected by alleged securities fraud between March 4, 2024 and May 23, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/savara-inc-lawsuit-submission ...